The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Colorectal Cancer Case Studies

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

Tanios Bekaii-Saab, MD
Published Online:Apr 26, 2016
Case 2 examines a 52-year-old woman newly diagnosed with metastatic CRC who is genotyped as part of her initial work up.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2


What strategies can be used to increase the percentage of patients who receive recommended RAS testing?

There are a number of ways to do this. One is to increase the level of education for pathologists for pathologists, as well as gastroenterologists and surgeons. So the folks who see the patients first before they send them to an oncologist, they need to know about the importance of this test. It should be more automatically thought of than it is today.

The other possibility, and its an emerging field, are the liquid biopsies. You take a serum and you send it for testing, and that could tell you if the tumor has a RAS mutation or not. Those tests are now more validated to reflect exactly what happens at the level of the tumor. This test is simple. You don't have to wait for tissue or go look for the tissue. There are some technical issues with these, but you draw the blood, you send it, and it takes about a couple of weeks for the results. I think that's one of the solutions eventually is the wider adoption of these liquid biopsies.

Unresectable Colon Cancer: Case 2

52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.

Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.